Revelation Biosciences Inc. Announces Exercise of Warrants for $11 Million in Gross Proceeds
Revelation Biosciences Reaches Agreement with FDA on Gemini Approval Pathway for AKI
Revelation Biosciences Inc. to Present at The International Conference on Advances in Critical Care Nephrology (AKI & CRRT 2026)
Revelation Biosciences Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Revelation Biosciences Announces Initiation of GMP Manufacturing of GEMINI and Placebo to Support Later Stage Clinical Development
Revelation Biosciences Has Reached A Quorum For Its December 3, 2025 Special Meeting
Revelation Biosciences On Track for End-of-Phase 1 Meeting With FDA Later This Year
Revelation Biosciences, Inc. Announces Financial Results for the three and nine months ended September 30, 2025
Revelation Biosciences Inc. Announces Cancellation of Adjournment of October 29, 2025 Special Meeting of Stockholders and New Record Date
Revelation Biosciences Inc. Announces Adjournment of October 15, 2025 Special Meeting of Stockholders to October 29, 2025
Revelation Biosciences Inc. Announces Exercise of Warrants for $9.6 Million in Gross Proceeds
Revelation Biosciences Announces Special Webcast to Review Positive Top-line Clinical Data
Reminder - Webcast/Conference Call to Discuss Fantastic PRIME Phase 1b Top-line Data
Revelation Biosciences Announces Groundbreaking Top-line Results from PRIME Clinical Study
Revelation Biosciences, Inc. Announces Financial Results for the three and six months ended June 30, 2025
Revelation Biosciences, Inc. Congratulates Its Former Chairman of the Board, George Tidmarsh, on His Appointment as the Head of the FDA Center for Drug Evaluation and Research
Revelation Biosciences Inc. Completes Dosing of Patients in PRIME Study
Revelation Biosciences Inc. Announces 1-for-3 Reverse Stock Split effective July 7, 2025
Revelation Biosciences, Inc. Announces Closing of $4 Million Public Offering
Revelation Biosciences, Inc. Announces Pricing of $4 Million Public Offering
